Furthermore, TAMs have been reported to be associated with the prognosis of patients with HCC; the low expression of CD86+ TAMs and high expression of CD206+ TAMs in HCC tissues are significantly related to clinical stage progression and prognosis [81]. This evidence concerns the gene MRC1 and hepatocellular carcinoma.